Advertisement
Advertisement
U.S. Markets close in 6 hrs 19 mins
Advertisement
Advertisement
Advertisement
Advertisement

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.36-0.12 (-1.85%)
As of 09:39AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.48
Open6.47
Bid6.32 x 1100
Ask6.90 x 1400
Day's Range6.36 - 6.47
52 Week Range2.46 - 10.60
Volume8,028
Avg. Volume247,301
Market Cap241.409M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

    Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cross species transduction for multiple capsids and characterization of the receptor for a leading capsid support human translation potential of TRACERTM capsids Catherine J. Mackey, Ph.D., appointed to Board of Directors Strong ba

  • GlobeNewswire

    Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

    Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Conference CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, t

  • GlobeNewswire

    Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

    CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate u

Advertisement
Advertisement